Type Public (LSE: SLN) Founded 1994 Number of employees 50 | Industry Pharmaceuticals Headquarters London, United Kingdom | |
 | ||
Website www.silence-therapeutics.com Stock price SLN (LON) 88.00 GBX 0.00 (0.00%)21 Mar, 2:36 PM GMT - Disclaimer Profiles | ||
Silence Therapeutics (AIM:SLN) is a biotechnology company that develops gene therapeutic technology based on RNA interference (RNAi). They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters based at 1 Lyric Square, London.
Contents
Profile
The targeting, delivery and ongoing structural modification of sequences are the three platforms for Silence Therapeutics’s RNAi therapeutic development. These three platforms are:
Silence Therapeutics develops these structural modifications using three exclusive licences from the University of Massachusetts Amherst.
History
In 2005, the company acquired Atugen AG based in Germany, changing the company name to Silence Therapeutics AG. More recently in January 2010, Silence Therapeutics merged with Intradigm Corporation, a privately held biotechnology company in the United States that developed systematic RNA interference.
Partnerships
Silence Therapeutics has multiple partnerships with other pharmaceutical companies, such as AstraZeneca, Pfizer/Quark Pharma and Dainippon Sumitomo.